Video

mHSPC VL

Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alicia Morgans presents the treatment of vulnerable/frail patients with metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC...
Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Caroline Clarke presents on health economics in metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Caroline S. Clarke, PhD, MSci, BA (Hons), Senior Research Associate in Health Economics, University College London, London, UK Related Content: APCCC 2022: Optimal Treatment for mHSPC from a Health Econo...
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Gert Attard presents on whether we need more granularity in mHSPC, and whether biology can help with treatment decisions. Biographies: Gert Attard, MD, PhD, FRCP, John Black Charitable Foundation Endowed Chair in Urological Cancer Research, University College London Cancer Institute, London, UK Related Content: APCCC...
Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Bertrand Tombal presents de-escalation strategies in the management of metastatic hormone-sensitive prostate cancer (mHSPC) Biographies: Bertrand Tombal, MD, PhD, Chairman of the Department of Surgery and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels,...
Treatment Intensification Strategies in mHSPC: Triplets and More APCCC 2022 Presentation - Christopher Sweeney Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Christopher Sweeney presents treatment intensification strategies in metastatic hormone-sensitive prostate cancer (mHSPC), focusing on triplet therapies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Related Content: APCCC 2022: Treatme...
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Treat like Low-Volume APCCC 2022 Presentation - Karim Fizazi Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Karim Fizazi presents when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC, we should treat these patients like low volume patients. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of...
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation? APCCC 2022 Presentation - Michael Hofman Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Hofman presents how frequently low-volume disease on conventional imaging becomes high-volume on next-generation imaging in the management of metastatic hormone-sensitive prostate cancer (mHSPC). Biographies: Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS, Molecular Imaging & Therapeutic Nuclear Medicine,...
The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong Details At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Andrew Armstrong presents the uptake of new treatment options for mHSPC in real life, including education, access, use, and diversity. Biographies: Andrew Armstrong, MD, Professor of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC Related Content: APCCC 2022: The...
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore Details Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT. Drs. Shore and Morgans speak about the clinical implications of this approval from a urologist's perspective. The approval was based on the overall survival data Matthew Smith presented at ASCO GU 2022 and the 32% reduction in mortal...
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal Details In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...

mHSPC VL

Login